Multicentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocol

Alicia Calderone, Wendy Stevens, David Prior, Harshal Nandurkar, Eli Gabbay, Susanna M Proudman, Trevor Williams, David Celermajer, Joanne Sahhar, Peter K K Wong, Vivek Thakkar, Nathan Dwyer, Jeremy Wrobel, Weng Chin, Danny Liew, Margaret Staples, Rachelle Buchbinder, Mandana Nikpour

ABSTRACT

Introduction: Systemic sclerosis (SSc) is a severe and costly multiorgan autoimmune connective tissue disease characterised by vasculopathy and fibrosis. One of the major causes of SSc-related death is pulmonary arterial hypertension (PAH), which develops in 12–15% of patients with SSc and accounts for 30–40% of deaths. In situ thrombosis in the small calibre peripheral pulmonary vessels resulting from endothelial dysfunction and an imbalance of anticoagulant and prothrombotic mediators has been implicated in the complex pathophysiology of SSc-related PAH (SSc-PAH), with international clinical guidelines recommending the use of anticoagulants for some types of PAH, such as idiopathic PAH. However, anticoagulation has not become part of standard clinical care for patients with SSc-PAH as only observational evidence exists to support its use. Therefore, we present the rationale and methodology of a phase III randomised controlled trial (RCT) to evaluate the efficacy, safety and cost-effectiveness of anticoagulation in SSc-PAH.

Methods and analysis: This Australian multicentre RCT will compare 2.5 mg apixaban with placebo, in parallel treatment groups randomised in a 1:1 ratio, both administered twice daily for 3 years as adjunct therapy to stable oral PAH therapy. The composite primary outcome measure will be the time to death or clinical worsening of PAH. Secondary outcomes will include functional capacity, health-related quality of life measures and adverse events. A cost-effectiveness analysis of anticoagulation versus placebo will also be undertaken.

Ethics and dissemination: Ethical approval for this RCT has been granted by the Human Research Ethics Committees of all participating centres. An independent data safety monitoring board will review safety and tolerability data for the duration of the trial. The findings of this RCT are to be published in open access journals.

Strengths and limitations of this study

- This is the first clinical trial ever to evaluate the efficacy, safety and cost-effectiveness of anticoagulation as adjunct treatment in systemic sclerosis-related pulmonary arterial hypertension (PAH).
- The blinded randomised placebo-controlled design of this trial is intended to minimise bias.
- The choice of apixaban 2.5 mg two times a day as the anticoagulant treatment is based on consideration of the risk to benefit ratio in systemic sclerosis-related PAH. However, this study is not intended to specifically evaluate the efficacy, safety and cost-effectiveness of other anticoagulant doses or drugs in this condition.
- The use of a composite clinical worsening primary end point and health-related quality of life as a secondary end point is in line with the most recent expert taskforce recommendations.
- Among the limitations of this study is the inclusion of patients with PAH of varying durations and not exclusively incident cases, and the use of self-reported health service usage in cost-effectiveness analysis. In addition, indirect costs are not quantified.

Pre-publication history for this paper is available online. To view these files please visit the journal online (http://dx.doi.org/10.1136/bmjopen-2016-011028).

Pre-registration number: ACTRN12614000418673, Pre-results.
INTRODUCTION

Scleroderma or systemic sclerosis (SSc) is a multiorgan autoimmune connective tissue disease (CTD) characterised by vasculopathy and fibrosis, which is estimated to affect over 2 million people worldwide, with some studies indicating a rising incidence.1–3 Owing to the multiorgan nature and chronicity of the disease, SSc is associated with significant morbidity and is one of the most costly rheumatic diseases.1–7 SSc is also a life-threatening condition that carries the greatest burden of case-based mortality among the rheumatic diseases, reducing life expectancy by an average of 16 years per male patient and 34.1 years per female patient.8 It is now well established that pulmonary arterial hypertension (PAH), a condition of increased resistance in the pulmonary vasculature, is one of the leading causes of death in SSc, accounting for 30–40% of deaths in this disease.9–13 Untreated, SSc-related PAH (SSc-PAH) may follow a rapidly fatal course, with death resulting from right ventricular failure and arrhythmias.9

So-called ‘advanced’ PAH therapies target mediators of the complex pathophysiology underlying PAH (figure 1), predominantly molecules responsible for vascular remodelling, that result in an imbalance between endogenous pulmonary vasoconstriction and vasodilation.14 15 In SSc-PAH, these advanced PAH therapies demonstrate improved survival, exercise capacity as measured by 6 min walk distance (6MWD) and health-related quality of life (HRQoL) outcomes, compared with placebo.14–16 Prior to the advent of advanced PAH therapies in the early 2000s, the 1-year survival of patients with SSc-PAH was 45%.17 Subsequently, a systematic review of all randomised controlled trials (RCTs) of advanced PAH therapies, including patients with primary ‘idiopathic’ PAH (iPAH) and PAH secondary to CTD (CTD-PAH), reported an absolute reduction in mortality of 39% (p=0.04) with specific PAH therapy compared with placebo.18 Further, two Australian observational studies have shown improved survival with combination PAH therapy compared with monotherapy in patients with iPAH and CTD-PAH (3-year survival 85% with combination therapy vs 60% with monotherapy in CTD-PAH).19 20 Thus, survival has improved dramatically since the introduction of advanced therapies. However, PAH still carries a high burden of morbidity and mortality.10 15 Importantly, SSc-PAH continues to display the poorest prognosis compared with iPAH and other CTD-PAH subgroups.21 22

In situ thrombosis is a likely contributor to the pathophysiology of SSc-PAH, with pulmonary vascular (venous and arterial) thrombosis in the small calibre peripheral pulmonary vessels appearing as a common histological feature in both iPAH and CTD-PAH tissue specimens (figure 2).23–25 While several observational studies, including the Australian Scleroderma Cohort Study, have suggested a survival benefit with anticoagulation in PAH, other observational studies have not supported this finding.19 26–31 However, many of the patients included in these studies were not on advanced PAH therapy, and the majority had iPAH.28 31 In contrast, the Australian Scleroderma Cohort Study data revealed a substantial survival benefit with anticoagulation when administered in conjunction with advanced PAH therapy.19 In this CTD-PAH cohort (95% of whom were patients with SSc-PAH), exhibiting a median survival of only 5 years, an estimated 5-fold reduction in mortality was observed with warfarin treatment, prescribed at physician discretion, over an average 2.6±1.8 years follow-up.19 Furthermore, in contrast to the support for

Figure 1 The pathophysiological targets of advanced PAH therapies. Pulmonary artery endothelial cell dysfunction impacts on vascular smooth muscle cell tone and remodelling in the following ways, targeted by the three main classes of advanced PAH therapy to prevent (--) or promote (+) the physiological mechanisms described in the centre of the diagram: (+++) overexpression of ET-1 has a potent vasoconstrictor effect. Thus, ETRAs such as bosentan and ambrisentan block vasoconstriction of pulmonary artery smooth muscle cells. (Lorem) Impaired production of NO is remedied by PDE-5 inhibitors such as sildenafil that enhance NO-mediated vasodilation. (--) Prostacyclin is a vasodilator with antiproliferative effects that is deficient in the setting of PAH. Prostacyclin analogues such as epoprostenol, treprostinil and iloprost therefore promote vasodilation in pulmonary smooth muscle cells and prevent vascular remodelling which may involve numerous cells, including platelets and fibroblasts. ET-1, endothelin-1; ETRA, ET-1 receptor antagonist; NO, nitric oxide; PAH, pulmonary arterial hypertension; PDE-5, phosphodiesterase type-5.
anticoagulation in European and American guidelines for treatment of iPAH, owing to the absence of RCT data, recommendations for anticoagulation in SSc-PAH are based on weak evidence and reflect a state of clinical equipoise among experts. Although pulmonary vascular pathobiology may be similar to that seen in iPAH, patients with SSc-PAH have other clinical features which may impact the risk to benefit ratio of anticoagulation. Hence, there is great variability in beliefs and prescribing habits regarding anticoagulation as adjunct therapy in SSc-PAH. The weight of preliminary evidence, societal costs and high morbidity of SSc-PAH demand an urgent resolution of this contentious issue through an RCT.

In the design of this RCT, several considerations favour the use of novel oral anticoagulants as safer, more effective and more convenient than warfarin for patients with SSc-PAH. Factor Xa is a pivotal component of the coagulation cascade, and oral factor Xa inhibitors such as apixaban and rivaroxaban, which are hypothesised to have antiplatelet and endothelial effects, may target multiple pathways critical to SSc-PAH pathogenesis. Oral factor Xa inhibitors may offer more stable blood levels than warfarin, assuming full compliance. These agents are administered at fixed doses, have fewer diet or drug interactions, are eliminated through multiple pathways and do not require routine international normalised ratio (INR) monitoring. The reliable bioavailability of the factor Xa inhibitors is particularly advantageous in patients with SSc, many of whom have gut hypomotility and bacterial overgrowth, which may affect warfarin and vitamin K absorption, resulting in unstable INRs. With up to 6% of patients with SSc exhibiting intestinal telangiectasias or gastric antral vascular ectasias which may bleed, the lower risk of gastrointestinal bleeding with apixaban, observed in large clinical trials of other patient groups, is reassuring. Finally, patients with SSc often have difficult venous access due to skin fibrosis and subcutaneous joint contractures. Such patients are typically reluctant to have the multiple venepunctures required for INR monitoring. Since oral factor Xa inhibitors do not require monitoring of blood levels and there is potential to blind treatment assignment for RCTs and participant retention in clinical trials could possibly increase.

Objective
The aim of this study is to evaluate the efficacy, safety and cost-effectiveness of treatment over 3 years with the novel oral anticoagulant apixaban (a factor Xa inhibitor) in SSc-PAH, by undertaking a multicentre, double-blind, placebo-controlled RCT. The intervention will occur on a background of advanced PAH therapy prescribed as standard of care for participants assigned to treatment and placebo arms.

METHODS AND ANALYSIS
Study design
The study is designed as a multicentre, participant-blinded and investigator-blinded, placebo-controlled phase III clinical trial to compare the efficacy, safety and cost-effectiveness of apixaban 2.5 mg twice daily versus placebo, randomised in a 1:1 ratio, over a treatment period of 3 years, as additional therapy in patients with SSc-PAH who are already on advanced pulmonary vasodilators. The study design and assessment timeline is illustrated in figure 3.

Study population
Study participants will be identified by cardiologists, rheumatologists and respirologists during the course of routine care at 13 Australian PAH treatment centres across six states (New South Wales, Queensland, South Australia, Tasmania, Victoria and Western Australia). Recruitment will take place over 24 months or until sample size requirements are met and participants will be treated for 36 months. Participants will be adult men and women with symptomatic SSc-PAH as defined by the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2013 classification criteria for SSc and international guidelines for diagnosis of PAH. Inclusion and exclusion criteria are listed in tables 1 and 2, respectively. Many of the exclusion criteria focus on reducing the risk of adverse bleeding events in the study population.

Randomisation and allocation concealment
Ethical considerations mandate background treatment with advanced PAH therapies as standard of care in all study participants. Since sites differ in rates of use of PAH-specific therapies, including combination therapy, randomisation will be stratified according to site, with the effect of various PAH therapies subsequently adjusted for in multiple regression analysis.
Randomisation to placebo or study drug in a 1:1 ratio will be performed by a statistician who is not associated with any study site, using computer-generated block randomisation, stratified according to study site. After the investigator obtains informed consent and confirms eligibility, patients who meet all inclusion criteria and none of the exclusion criteria will be assigned to study treatment by the site pharmacist at baseline visit, according to the site randomisation schedule.

Participants, healthcare providers, investigators, data collectors and outcome assessors will be blinded to treatment assignment. To ensure allocation concealment, the appearance of the investigational drug (apixaban, BMS-562247, Bristol-Myers Squibb Limited (BMS)) and its packaging will be indistinguishable from the matching placebo, both manufactured by BMS. The labelling and packaging of apixaban and matching placebo will be conducted according to Good Manufacturing Practice, Good Clinical Practice and national regulatory requirements, coordinated by the study lead pharmacy.

A password-protected restricted access electronic database of all randomisation codes will be kept for emergency unblinding purposes. If any participant experiences a medical emergency where management would be improved by knowledge of the blinded treatment assignment, unblinding will be available 24 hours per day. A set of tamper-proof sealed envelopes containing the blinding code for each participant will be kept at each site in case contact with the database server fails. The integrity of these sealed envelopes will be periodically checked. A log of every access to the unblinding codes will be kept and all requests for unblinding must be clearly justified.

**Treatment exposure and compliance**

The study drug will be administered orally, twice daily as 2.5 mg tablets of apixaban or matching placebo, with a dose interval of ~12 hours. Participants will be asked to return all the unused study drug at follow-up visits and to self-report any missed doses of therapy. Study drug adherence will be assessed by recording quantities of the returned study drug at each follow-up visit. Participants will cease using the study drug 36 months after initiation at the baseline visit.

The study design mandates the concomitant use of at least one advanced pulmonary vasodilator, such as an...
endothelin-1 receptor antagonist (ETRA) and/or a phosphodiesterase type-5 (PDE-5) inhibitor. However, these therapies must be at a stable dose for at least 2 months prior to baseline. Permissible concomitant medication includes diuretic therapy, provided that a medication includes diuretic therapy, provided that a

### Table 1 The SPHInX study inclusion criteria

<table>
<thead>
<tr>
<th>Item</th>
<th>Characteristics of eligible participants*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Male and female patients aged from 18 to 75 years inclusive</td>
<td></td>
</tr>
<tr>
<td>2. Scleroderma defined by the ACR/EULAR 2013 classification criteria</td>
<td></td>
</tr>
<tr>
<td>3. RHC at any time prior to baseline demonstrating the following haemodynamic characteristics in line with current international guidelines for diagnosis of PAH:</td>
<td>i. resting mPAP ≥ 25 mm Hg and</td>
</tr>
<tr>
<td></td>
<td>ii. resting PVR ≥ 3 woods units and</td>
</tr>
<tr>
<td></td>
<td>iii. resting PCWP or LVEDP ≤ 15 mm Hg, or</td>
</tr>
<tr>
<td></td>
<td>iv. If PVR cannot or has not been measured, then mPAP ≥ 30 mm Hg with PCWP or LVEDP ≤ 15 mm Hg</td>
</tr>
<tr>
<td>4. 6 min walk distance &gt; 50 m at screening and/or baseline</td>
<td></td>
</tr>
<tr>
<td>5. Other causes of PAH, in particular CTEPH, must have been previously excluded by either a V/Q scan or CTPA</td>
<td></td>
</tr>
<tr>
<td>6. Currently taking at least one of the ETRA or PDE-5 inhibitor medications in a stable dose for the 2 months prior to baseline (bosentan, ambrisentan or macitentan, and/or sildenafil or tadalafil)</td>
<td></td>
</tr>
<tr>
<td>7. Female participants of childbearing potential must test negative for pregnancy</td>
<td></td>
</tr>
<tr>
<td>8. Male and female participants of childbearing potential must agree to use a highly effective method of contraception throughout the study and for at least 28 days after the last dose of the study drug. A participant is of childbearing potential if, in the opinion of the investigator, he/she is biologically capable of having children and is sexually active</td>
<td></td>
</tr>
<tr>
<td>9. Female participants who are not of childbearing potential must meet at least one of the following criteria:</td>
<td>i. Have undergone documented hysterectomy and/or bilateral oophorectomy, or</td>
</tr>
<tr>
<td></td>
<td>ii. Have medically confirmed ovarian failure, or</td>
</tr>
<tr>
<td></td>
<td>iii. Achieved postmenopausal status, defined as cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause and have a serum follicle-stimulating hormone level within the laboratory’s reference range for postmenopausal females</td>
</tr>
</tbody>
</table>

*All items must be present for eligibility in the clinical trial.

ACR, American College of Rheumatology; CTEPH, chronic thromboembolic pulmonary hypertension; CTPA, CT pulmonary angiogram; ETRA, endothelin-1 receptor antagonist EULAR, European League Against Rheumatism; LVEDP, left ventricular end diastolic pressure; mPAP, mean pulmonary arterial pressure; PAH, pulmonary arterial hypertension; PCWP, pulmonary capillary wedge pressure; PDE-5, phosphodiesterase type-5; PVR, pulmonary vascular resistance; RHC, right heart catheterisation; V/Q, ventilation/perfusion.

Table 1 The SPHInX study inclusion criteria

Concomitant medications will be monitored closely from 1 month following the baseline visit. Participants will be required to self-report all changes to therapy throughout the study treatment period using a healthcare usage diary. Initiation of any new PAH-specific treatment or a dose increase of such a drug without adjudicated clinical worsening of PAH is strongly discouraged during the study period. If continued administration of the study drug is believed to be contrary to the best interests of the participant (ie, adverse event, diagnostic or therapeutic procedure, laboratory abnormalities, pregnancy, unblinding or withdrawal of consent), interruption or permanent discontinuation of the study drug is mandated. Participants will resume the study drug as long as the investigator feels it is safe for them to do so and no more than 8 weeks of study treatment has been missed. Participants who prematurely discontinue the study drug for any reason will not be replaced and, unless they withdraw consent, will continue to be followed up six-monthly until 36 months from baseline.

Study assessments

The study assessment schedule is illustrated in figure 2, starting with screening and ending with follow-up.
30 days after permanent cessation of the study drug. Additional visits may also take place at any time during the treatment period in case of a suspected CWE. Screening assessments to confirm study eligibility may occur at any time prior to randomisation, or be completed on the same day as the baseline visit. Adverse event surveillance is prioritised at follow-up assessments. With reference to their healthcare usage diary, participants will be required to self-report all healthcare usage (ie, visits to healthcare/allied health practitioners and hospitalisations), side effects and pregnancy test results if applicable. Data collection requirements over the duration of the study are described in Table 3. All data collected will be entered de-identified into a customised electronic case report form, created on the REDCap platform, that is password protected and stored securely on the central server at St Vincent’s Hospital Melbourne. Hard copies of source documents will be retained for 5 years following the end of the study.

The 6 min walk test (6MWT) will be performed in a standardised, non-encouraged fashion, measuring the walking distance covered by the patient during a 6 min period followed immediately by the Borg dyspnoea index, which rates dyspnoea severity on a visual analogue scale from ‘0’ to ‘10’. The following validated HRQoL questionnaires will be completed by the patient: the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36), the scleroderma-modified Stanford Health Assessment Questionnaire (sHAQ57 58 and the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR).59 The 6MWT and HRQoL questionnaires will be omitted from visit 2 (1 month post-randomisation), which will serve as an abridged safety assessment only, unless there is a suspected CWE.

Serum and platelet-free plasma samples collected at baseline, 6-month and 24-month follow-up visits will be stored at −80°C for the N-terminal prohormone of the B-type natriuretic peptide (NT-proBNP) assay and

---

Table 2  The SPHInX study exclusion criteria

<table>
<thead>
<tr>
<th>Item</th>
<th>Characteristics of ineligible participants*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Pulmonary hypertension due to any other cause than SSc</td>
</tr>
<tr>
<td>2</td>
<td>Moderate or severe obstructive lung disease, ie, FEV1/FVC ratio &lt;70% and FEV1&lt;65% of predicted value after bronchodilator administration</td>
</tr>
<tr>
<td>3</td>
<td>Moderate or severe restrictive lung disease, ie, FVC&lt;70% of predicted value, provided that the HRCT scan demonstrates moderate-to-severe changes of ILD, or FVC&lt;60% of predicted value, regardless of the HRCT result</td>
</tr>
<tr>
<td>4</td>
<td>Moderate or severe hepatic impairment (ie, Child-Pugh class B or C)</td>
</tr>
<tr>
<td>5</td>
<td>Documented left ventricular dysfunction (ie, ejection fraction &lt;45%)</td>
</tr>
<tr>
<td>6</td>
<td>Severe renal insufficiency (estimated creatinine clearance &lt;25 mL/min, or serum creatinine &gt;200 µmol/L)</td>
</tr>
<tr>
<td>7</td>
<td>Receiving any investigational drugs within 1 month prior to or at baseline</td>
</tr>
<tr>
<td>8</td>
<td>Receiving continuous intravenous epoprostenol or iloprost at baseline or have planned to initiate this therapy within the next 3 months</td>
</tr>
<tr>
<td>9</td>
<td>Psychotic, addictive or other disorder limiting the ability to provide informed consent or to comply with study requirements</td>
</tr>
<tr>
<td>10</td>
<td>Life expectancy due to another condition of &lt;12 months</td>
</tr>
<tr>
<td>11</td>
<td>Females who are breast feeding or pregnant (positive pre-randomisation serum pregnancy test) or plan to become pregnant during the study</td>
</tr>
<tr>
<td>12</td>
<td>Known hypersensitivity to drugs of the same class as the study drug, or any of the excipients of the drug formulations</td>
</tr>
<tr>
<td>13</td>
<td>Gastrointestinal tract bleeding in the past 12 months due to GAVE or unexplained iron deficiency anaemia (in the past 12 months)</td>
</tr>
<tr>
<td>14</td>
<td>Haemoglobin &lt;100 g/L at screening</td>
</tr>
<tr>
<td>15</td>
<td>Participants at significant risk of falls in whom anticoagulation would be inappropriate</td>
</tr>
<tr>
<td>16</td>
<td>Participants who have received any oral or subcutaneous anticoagulants (eg, warfarin, apixaban, rivaroxaban, dabigatran, enoxaparin, dalteparin or heparin) for more than 3 months since the diagnosis of PAH</td>
</tr>
<tr>
<td>17</td>
<td>Participants with a prosthesis valve who require long-term oral anticoagulation.</td>
</tr>
<tr>
<td>18</td>
<td>Participants who are currently in atrial fibrillation.</td>
</tr>
<tr>
<td>19</td>
<td>Participants with PAH not on either an ETRA or PDE-5 inhibitor</td>
</tr>
<tr>
<td>20</td>
<td>Participants with known bleeding disorders and/or platelet count &lt;100 at screening and/or INR&gt;1.2 at screening.</td>
</tr>
<tr>
<td>21</td>
<td>Brain, spinal or eye surgery within the past 1 month</td>
</tr>
<tr>
<td>22</td>
<td>Uncontrolled systemic hypertension defined as either systolic blood pressure ≥180 mm Hg or diastolic blood pressure ≥110 mm Hg at screening</td>
</tr>
<tr>
<td>23</td>
<td>Documented episode of either pulmonary embolus or deep venous thrombosis since diagnosis of PAH</td>
</tr>
<tr>
<td>24</td>
<td>Participants with a current, or active in the past 1 month, major bleed that is life-threatening, causes chronic sequelae or consumes major healthcare resources, as defined by the International Society on Thrombosis and Haemostasis</td>
</tr>
</tbody>
</table>

*Participants must not meet any of the exclusion criteria for eligibility in the clinical trial. ETRA, endothelin-1 receptor antagonist; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GAVE, gastric antral vascular ectasiae; HRCT, high resolution CT; ILD, interstitial lung disease; INR, international normalised ratio; PAH, pulmonary arterial hypertension; PDE-5, phosphodiesterase type-5.
exploratory biomarker testing. Factor Xa levels in platelet-free plasma specimens will also be compared between baseline and 6 months to reflect bioavailability of apixaban in the treatment group. Anti-factor Xa assays and biomarker assays will be performed for all samples in triplicate, in a single laboratory, at the conclusion of the study.

Outcome measures
In line with the Task Force on Endpoints and Clinical Trial design recommendation for phase III trials at the Fourth World Symposium on pulmonary hypertension in Dana Point, California, a composite primary end point will be employed, providing measurable parameters to support an independent adjudication of ‘time to clinical worsening’. The primary end point will be time from randomisation up to 36 months to the first adjudicated CWE from the composite parameters listed in table 4. CWEs will be adjudicated in a blinded fashion by an end point adjudication committee consisting of four of the investigators (MN, WS, DP, SMP) who will adjudicate each event independently and then meet to discuss any that were not unanimously agreed on. The study drug will be continued in a blinded fashion after a CWE is adjudicated, to enable quantification of the total number of CWEs during the study period as a secondary end point.

Selection of secondary end points was informed by Expert Panel recommendations for a ‘core set’ of outcome measures to be used in clinical trials of new therapies in SSc-PAH. Secondary efficacy end points include all-cause mortality; absence of worsening in the NYHA/WHO functional class; change in 6MWD and the Borg dyspnoea index; change in the SF-36, sHAQ and CAMPHOR questionnaire subscales. Secondary end point comparisons will be evaluated from baseline to each of the 12-month, 24-month and 36-month follow-up time points, adjusted for time since diagnosis of PAH. The last valid post-baseline value will be carried forward to compensate for any missing values at each time point.

Safety and tolerability end points will comprise treatment-emergent adverse events (serious and non-serious) including marked laboratory abnormalities up to 7 days after the last study drug intake, adverse events leading to premature discontinuation of study drug, change from baseline to end of study in vital signs. Health economic end points will include number per year, and associated costs, of all-cause and PAH-related hospitalisations and in-patient hospital days, general practitioner, specialist visits, allied health service usage and initiation of new medications.

In participants who discontinue the study, where possible, CWE will be captured every 6 months to the end of 36 weeks from enrolment.

Sample size estimation
Sample size was calculated based on a comparison of two survival curves for the primary outcome of clinical worsening over 3 years, applying the method of Rubinstein et al. This method uses median survival rather than event rate. The following variables were used to determine sample size: (1) α=0.05, two-sided; (2)
β=0.2 (power 80%); (3) difference to be detected expressed as an HR of placebo:treatment=2.0, based on previous Australian observational data, but reduced by 60% to provide a more conservative estimate for the purposes of an RCT;¹⁹ (4) control group median survival=45.6 months also based on previous Australian observations;¹⁹ (5) ratio of participants randomised to control and experimental groups=1:1; (6) block randomisation stratified according to 13 centres; (7) duration of recruitment=24 months; (8) duration of follow-up=36 months; (9) expected attrition=10%. However, substantial loss to follow-up is unlikely as trial participants are required to attend for regular review to continue receiving PAH therapy subsidised under the Pharmaceutical Benefit Scheme (PBS). Based on these assumptions, it is expected that 65 events will be observed in this study and a total sample size of 170 participants (85 per arm) is required.

Statistical analyses
The hypothesis to be tested is: null hypothesis (H0)=the distribution of the primary end point is the same in the treatment groups; alternative hypothesis (H1)=the distribution of the primary end point in the placebo group differs from the distribution in the active group. The ratio of the hazards of a CWE in the two groups is not expected to change over time. Therefore, the use of methods requiring proportional hazards is considered appropriate. The main analyses for the primary and secondary end points will test the null hypothesis by means of the log-rank and Wilcoxon tests, performed in the intention-to-treat population, which includes all participants randomised. No adjustment for covariates is planned for the primary analysis. However, in order to evaluate the robustness of results, the primary end point will also be analysed on the per-protocol set, with 80% used as the cut-off to define an adherent patient. Supportive analyses will be conducted using appropriate covariates (eg, the date PAH was first diagnosed by right heart catheterisation (RHC), the start date of concomitant PAH medications and combination PAH therapy) in a Cox regression model.

The time to occurrence of the first CWE up to 30 days after the last study drug intake will be described by the Kaplan-Meier survival curves. The HR of placebo:treatment with two-sided 95% CIs of the event-free proportion estimates at relevant time points will be presented for each treatment group in graphical and tabular form, in addition to descriptive statistics to summarise patient and disease characteristics. No imputation method will be used for the primary end point and if there is a missing assessment (eg, no confirmatory 6MWT or NYHA/WHO FC) for a CWE, the end point adjudication committee will be responsible for qualifying or disqualifying such events before primary end point analysis. Patients without a CWE permanently discontinuing treatment will be censored 30 days after study treatment discontinuation or date of last contact.

Differences in baseline characteristics of patients in the apixaban and control arms will be compared using univariate methods ($\chi^2$, t-tests and Mann-Whitney tests). Univariate and multivariable methods (logistic and linear regression) will be used to compare differences in echocardiographic parameters, 6MWD, NYHA/WHO FC, NT-proBNP level and HRQoL in the apixaban and control arms at 1, 2 and 3 years. Covariates included in multivariable analyses will include specific PAH therapy, cardiovascular medications and immunosuppressives. Sensitivity analyses will be performed to evaluate the effect of poor treatment adherence and loss to follow-up in patients whose fate is unknown at the end of the study. No interim efficacy analyses are planned at this stage. However, a planned re-estimation of the sample size may be performed prior to the expected closure of

---

<table>
<thead>
<tr>
<th>Table 4</th>
<th>Definition of measurable composite primary end point parameters</th>
</tr>
</thead>
<tbody>
<tr>
<td>Item</td>
<td>Possible clinical worsening events</td>
</tr>
<tr>
<td>1.</td>
<td>Death (all-cause mortality)</td>
</tr>
<tr>
<td>2.</td>
<td>Hospitalisation for worsening of PAH due to either:</td>
</tr>
<tr>
<td></td>
<td>i. Need for lung transplantation or balloon atrial septostomy, or</td>
</tr>
<tr>
<td></td>
<td>ii. Initiation of parenteral (subcutaneous and intravenous) prostanoid therapy or chronic oxygen therapy</td>
</tr>
<tr>
<td>3.</td>
<td>Disease progression defined by the combination of at least two of the following components:</td>
</tr>
<tr>
<td></td>
<td>i. Reduction from baseline in 6MWD by 15%, confirmed by two consecutive 6MWTs carried out on different days, ideally within 2 weeks of one another</td>
</tr>
<tr>
<td></td>
<td>ii. Worsening of PAH symptoms included at least one of the following parameters:</td>
</tr>
<tr>
<td></td>
<td>a). Either an increase from baseline in the NYHA/WHO functional class (except for participants already in functional class IV), or</td>
</tr>
<tr>
<td></td>
<td>b). Appearance/worsening of signs/symptoms of right heart failure</td>
</tr>
<tr>
<td></td>
<td>iii. Need for additional PAH-specific therapy that may include inhaled prostanoids, PDE-5 inhibitors, ETRAs or intravenous diuretics</td>
</tr>
</tbody>
</table>

Any of the above singular events, or combinations of events, may be adjudicated as clinical worsening events within the composite primary end point for the first such event, or as a secondary efficacy end point for subsequent events.

6MWD, 6 min walk distance; 6MWT, 6 min walk test; ETRA, endothelin-1 receptor antagonist; PAH, pulmonary arterial hypertension; PDE-5, phosphodiesterase type-5.
recruitment, based on the observed blinded event rate in the composite end point.

Predefined subgroup analyses include a comparison of efficacy and safety in incident versus prevalent PAH, limited versus diffuse SSc disease subtypes and according to the autoantibody profile (anti-centromere anti-nuclear antibody vs anti-topoisomerase antibody). All statistical analyses will be performed by a biostatistician using STATA software.

**Cost-effectiveness analysis**

On completion of the RCT, a health economic analysis will be undertaken to determine the incremental cost-effectiveness ratio, in terms of ‘net costs’ per unit of ‘health gain’. Net costs will comprise the costs of treatment with apixaban and advanced PAH therapies for the duration of life-years gained, minus costs saved from hospitalisation and health service usage in the same 3-year time period. In order to enable this type of analysis, we will collect detailed usage data for medications, primary care, outpatient consultations, emergency department and elective hospitalisations, through participant health service usage diaries, questionnaires administered at study contact and source databases of the participating hospitals. Since actual costs of health service usage are not recorded, in cost-effectiveness analysis, we are making the assumption that the unit cost assigned to each service in the Medicare Benefits Schedule (MBS) is an accurate estimate of true costs.

Collection of time-to-event data and HRQoL data will enable calculation of quality-adjusted life years (QALYs) gained by the inclusion of anticoagulation therapy. Depending on the findings of the initial cost-effectiveness analysis, further economic modelling beyond 3 years, using the Markov approach, may be required.

We will be applying a 5% annual discount rate to projected future costs and benefits. We will undertake sensitivity analyses to test the robustness of our cost-effectiveness results, and to identify key input parameters to which the results are most sensitive. Both ‘one-way’ sensitivity analyses and ‘multi-way’ probabilistic sensitivity analyses will be undertaken.

**Ethics, safety monitoring, auditing and access to data**

Ethical approval of this trial has been acknowledged by the Governance offices of all hospitals involved in the trial (Fiona Stanley Hospital, Gold Coast University Hospital, Liverpool Hospital, Monash Health, Royal Adelaide Hospital, Royal Hobart Hospital, Royal Prince Alfred Hospital, The Alfred Hospital and The Queen Elizabeth Hospital). The findings of this RCT are to be published in open access journals, with none of the participants identifiable.

An independent Data and Safety Monitoring Board (DSMB), comprising a rheumatologist, haematologist, cardiologist and gastroenterologist, will review unblinded safety and tolerability data at three-monthly intervals to ensure safety of participants for the duration of the study. Members of the DSMB are independent of the study investigators and are free of competing interests. A formal DSMB charter has been produced for this study.

The randomisation code will not be broken and made available to investigators, including the study statistician, until after data analysis is complete.

The project coordinator based at St Vincent’s Hospital Melbourne will audit the trial conduct and data entry every 3–4 months and will undertake site visits. At this stage, no independent audit of trial conduct is planned but would occur at the request of the DSMB or regulatory bodies.

Only the lead chief investigator, trial coordinator and biostatistician will have access to the final unblinded trial data set for the purpose of analysis and dissemination of the findings from this study. None of these team members will have access to unblinded trial data prior to the completion of the study.

**Communication with investigators and dissemination of findings**

Any protocol modifications such as changes to eligibility criteria and analysis plans will be communicated by the lead chief investigator (MN) to the principal and associated investigators, and affected trial participants, through personal communication including emails and teleconferences and circulation of written documents including an amended study protocol. Authorship of papers arising from this study will be based on contribution to the study including intellectual content.

**Study limitations**

Limitations of this study include the inclusion of patients with PAH of varying durations and not exclusively incident cases, as well as the use of self-reported health service usage in cost-effectiveness analysis. In addition, in this study, indirect costs are not quantified.

**DISCUSSION**

The design of this clinical trial was not without its challenges. Numerous studies have demonstrated that survival in SSC-PAH declines precipitously over the first 3 years following diagnosis and thereafter plateaus, with an overall median survival of 5 years.19 21 22 62 66 Furthermore, registry studies have shown that prevalent cohorts of patients with PAH have better overall survival than incident cohorts, suggesting that there may be survivor bias in patients with long-standing PAH.19 Therefore, in an RCT of a novel therapy for SSc-PAH where the end point is a combination of mortality and clinical worsening, it would be ideal to limit enrolment to those with <3 years’ duration since diagnosis of PAH on RHC. However, given the low disease prevalence, this restriction could limit enrolment of an appropriate sample size in a timely manner. Despite these more generous inclusion criteria, the recruitment of a sufficient
number of patients to power this clinical trial remains the biggest challenge to its timely completion. The inves-
tigators are currently in the process of enlisting more recruitment sites to meet sample size requirements.

Since the novel oral anticoagulants are unable to be readily reversed, safety considerations were of utmost importance to study design. The overall drug safety profile indicates that apixaban is generally well tolerated with an elimination half-life of 12 hours.\textsuperscript{39} For stroke prevention in atrial fibrillation, apixaban administered in a ‘full dose’ (5 mg two times a day) has been demonstrated to be superior to warfarin for stroke prevention (p=0.01), with lower risk of bleeding (p<0.001).\textsuperscript{47} Similarly, there is emerging evidence that apixaban administered in ‘low dose’ (2.5 mg two times a day) may yield comparable efficacy to full-dose apixaban in certain clinical settings, such as thromboprophylaxis postarthroplasty or treatment of venous thromboembolism, with no increased risk of bleeding.\textsuperscript{45, 46, 52} Furthermore, in acute coronary syndromes, full-dose apixaban demonstrated a 2.45-fold increased risk of bleeding compared with placebo (p=0.005), whereas an increased risk of bleeding was not observed with low-dose treatment (p=0.09).\textsuperscript{53} Therefore, in our study, treatment comprising ‘low-dose’ apixaban should offer safety comparable to placebo, without compromising efficacy.

While a comparison with warfarin would have been interesting, from a practical and safety point of view, this was not possible. First, SSc-PAH is an infrequent condition and the addition of a third arm to the study would have increased sample size requirements, posing a serious threat to the feasibility of this study. Furthermore, two recently published studies have cast doubt over the safety of warfarin relative to its potential efficacy in SSc-PAH, suggesting that this treatment may in fact be harmful in this group of patients.\textsuperscript{29, 30} Possible reasons for this include the presence of SSc disease features such as gastrointestinal tract hypomotility and bacterial overgrowth affecting the absorption of warfarin, and the presence of gastric antral vascular ectasia and intestinal telangiectasia, which place patients at risk of gastrointestinal bleeding. For these reasons, as well as those discussed earlier, we have not included a warfarin arm in this trial.

Non-anticoagulant effects of heparins have been described.\textsuperscript{57} The potential of such actions is currently being investigated for the novel anticoagulants, further supporting our choice of anticoagulant in this study.\textsuperscript{68} The clinical impact of this study is likely to be realised in the near term and the scope for cost-savings from reduced need for hospitalisations is considerable. Owing to the high cost of pharmacotherapy in SSc-PAH, it was important to build a health economic analysis into this study to determine cost-effectiveness of adjunct anticoagulation. If anticoagulant therapy is successful at prolonging life in SSc-PAH, patients will spend a greater period of time on costly advanced PAH-specific therapies (typically approaching $A40 000 per drug, per patient year).\textsuperscript{69, 70} Therefore, HRQoL outcomes must be balanced against these costs. In Australia, there is no official threshold for incremental cost-effectiveness ratios, although $A50 000 per QALY saved is commonly used. The WHO recommends the use of gross domestic product per capita as a starting point to consider cost-effectiveness thresholds for a country, which for Australia at present is $A88 000.\textsuperscript{71}

This study seeks to determine the efficacy of a novel therapy with the goal of improving survival in a disease with very high short-term mortality. Until now, there have been no published RCTs of anticoagulation in SSc-PAH and there are no other trials currently registered in the WHO trials portal. Blinding of treatment assignment is an innovative feature of our study design as the majority of oral anticoagulation studies have been open label. Positive findings in this study may provide a rationale for further studies of factor Xa inhibition in other pulmonary vascular diseases, including iPAH. Thus, positive findings may have far-reaching implications beyond SSc. If the findings are negative, patients will be spared the potential risk, inconvenience and cost of anticoagulation. Since 30% of patients with SSc-PAH are being anticoagulated at present in clinical practice,\textsuperscript{19} this presents a unique situation where a negative study may be as important in terms of changing practice as a positive study. Regardless of the outcome, our study has the potential to redefine the standard of care in a disease entity where there is much uncertainty.

Author affiliations
\textsuperscript{1}Department of Rheumatology, St Vincent’s Hospital Melbourne, Melbourne, Victoria, Australia
\textsuperscript{2}Department of Cardiology, St Vincent’s Hospital Melbourne, Melbourne, Victoria, Australia
\textsuperscript{3}The University of Melbourne Department of Medicine at St Vincent’s Hospital Melbourne, Melbourne, Victoria, Australia
\textsuperscript{4}Australasian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, Victoria, Australia
\textsuperscript{5}The University of Notre Dame, Fremantle, Western Australia, Australia
\textsuperscript{6}Institute for Respiratory Health, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
\textsuperscript{7}Department of Rheumatology, Royal Adelaide Hospital, North Terrace, Adelaide, South Australia, Australia
\textsuperscript{8}University of Adelaide Discipline of Medicine at Royal Adelaide Hospital, North Terrace, Adelaide, South Australia, Australia
\textsuperscript{9}Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital, Monash University, Prahran, Victoria, Australia
\textsuperscript{10}Department of Cardiology, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
\textsuperscript{11}Department of Rheumatology, Monash Health and Monash University, Clayton, Victoria, Australia
\textsuperscript{12}Mid-North Coast Arthritis Clinic, Coffs Harbour, New South Wales, Australia
\textsuperscript{13}Faculty of Medicine, Rural Clinical School, University of New South Wales, Coffs Harbour, New South Wales, Australia
\textsuperscript{14}Department of Rheumatology, Liverpool Hospital, Liverpool, New South Wales, Australia
\textsuperscript{15}School of Medicine, University of Western Sydney, Penrith, New South Wales, Australia
\textsuperscript{16}Department of Cardiology, Royal Hobart Hospital, Hobart, Tasmania, Australia
REFERENCES


